选择语言

Human IGF-II Protein, Fc Tag

用户评价
货号-规格
价格
Qty.
IG2-H4260-100ug
¥2100.00
IG2-H4260-1mg (500ug X 2)
¥13440.00
合计0件 产品金额¥ 0

产品详情

  • 分子别名(Synonym)

    IGF2,C11orf43,FLJ22066,FLJ44734,IGF-II,PP9974

  • 表达区间及表达系统(Source)

    Human IGF-II, Fc Tag (IG2-H4260) is expressed from human 293 cells (HEK293). It contains AA Ala 25 - Glu 91 (Accession # P01344-1).

    Request for sequence
  • 蛋白结构(Molecular Characterization)

    IGF-II Structure

    This protein carries a human IgG1 Fc tag at the N-terminus.

    The protein has a calculated MW of 34.4 kDa. The protein migrates as 35-38 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • 偶联(Conjugate)

    Unconjugated

  • 内毒素(Endotoxin)

    Less than 1.0 EU per μg by the LAL method.

  • 纯度(Purity)

    95% as determined by SDS-PAGE.

  • 制剂(Formulation)

    Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, pH7.5 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • 重构方法(Reconstitution)

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • 存储(Storage)

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • 质量管理控制体系(QMS)

    1. 质量管理体系(ISO, GMP)
    2. 质量优势
    3. 质控流程

产品展示

  • 电泳(SDS-PAGE)

    IGF-II SDS-PAGE

    Human IGF-II, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

  • 活性(Bioactivity)-ELISA

     IGF-II ELISA

    Immobilized Human IGFBP-3, His Tag (Cat. No. IG3-H52H9) at 0.5 μg/mL (100 μL/well) can bind Human IGF-II, Fc Tag (Cat. No. IG2-H4260) with a linear range of 1.2-39 ng/mL (QC tested).

    Protocol
  •  IGF-II ELISA

    Immobilized Human IGF-II, Fc Tag (Cat. No. IG2-H4260) at 5 μg/mL (100 μL/well) can bind Human IGF-II R Protein, His Tag (Cat. No. IGR-H52H3) with a linear range of 0.002-0.078 μg/mL (Routinely tested).

    Protocol
  •  IGF-II ELISA

    Immobilized Human IGF-II, Fc Tag (Cat. No. IG2-H4260) at 5 μg/mL (100 μL/well) can bind Biotinylated Human IGFBP-4 Protein, His,Avitag (Cat. No. IG4-H82E3) with a linear range of 2-40 ng/mL (Routinely tested).

    Protocol

用户评价
发表评论

背景介绍

Insulin-like growth factor 2 (IGF-2) is also known as Somatomedin-A, IGF-II, PP9974, and is one of three protein hormones that share structural similarity to insulin. IGF-2 exerts its effects by binding to the IGF-1 receptor. IGF2 may also bind to the IGF-2 receptor (also called the cation-independent mannose 6-phosphate receptor), which acts as a signalling antagonist; that is, to prevent IGF2 responses. The major role of IGF2 is as a growth promoting hormone during gestation. In the process of Folliculogenesis, IGF2 is created by Theca cells to act in an autocrine manner on the theca cells themselves, and in a paracrine manner on Granulosa cells in the ovary. IGF2 promotes granulosa cell proliferation during the follicular phase of the menstrual cycle, acting alongside Follicle Stimulating Hormone (FSH). After ovulation has occurred, IGF-2 promotes progesterone secretion during the luteal phase of the menstrual cycle together with Luteinizing Hormone (LH). Thus, IGF2 acts as a Co-hormone together with both FSH and LH. IGF-2 may play a key role in memory and could potentially be used to treat Alzheimer's Disease. It is sometimes produced in excess in islet cell tumours, causing hypoglycemia. Doege-Potter syndrome is a paraneoplastic syndrome in which hypoglycemia is associated with the presence of one or more non-islet fibrous tumors in the pleural cavity. has been shown to interact with IGFBP3 and Transferrin.

前沿进展

 
药物研发进展
  • 英文全称:

    Insulin-like growth factor II

  • 中文全称:

    胰岛素样生长因子Ⅱ

  • 种类:

  • 上市药物数量:

    0 详情

  • 临床药物数量:

    1 详情

  • 最高研发阶段:

    临床二期

联系我们
项目合作
查看更多项目
  • 产品SKU
  • 产品详情
  • 产品展示
  • 用户评价
  • 背景介绍